Profile: KAI Pharmaceuticals, Inc. is a biology-based product-driven biopharmaceutical company that develops therapeutics targeting protein kinase C. We offer protein kinase C related therapeutics for life-threatening and poorly addressed diseases. Our KAI-9803 is an isozyme-selective delta protein kinase C (äPKC) inhibitor designed to reduce ischemia and reperfusion injury during treatment of acute myocardial infarction.
2 Products/Services (Click for related suppliers)
| |||||
• | Epsilon Protein Kinase C Activator | • | Protein Kinase C Inhibitors |